Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial - Takeaways - MDSpire

Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial

  • By

  • Rajesh Pahwa

  • Elena Moro

  • Alberto J. Espay

  • Andrew Evans

  • Marie Saint-Hilaire

  • Diego Torres-Russotto

  • Raymond Sanchez

  • Matthew Leoni

  • Sridhar Duvvuri

  • Cari Combs

  • Ih Chang

  • Stacey Tringali

  • Joey Boiser

  • Cindy Zadikoff

  • Angelo Antonini

  • May 1, 2026

  • 0 min

Share

  • 1

    Tavapadon is a selective D1/D5 partial agonist showing promise for improving motor symptoms in early Parkinson's disease.

  • 2

    The TEMPO-1 trial evaluated fixed doses of tavapadon for efficacy, safety, and tolerability in early Parkinson's disease patients.

  • 3

    Participants in the trial were adults aged 40 to 80 with early Parkinson's disease, naive to or minimally treated with dopaminergic therapies.

  • 4

    The primary endpoint was the change in MDS-UPDRS scores from baseline to week 26, assessing motor function and daily living experiences.

  • 5

    Safety endpoints included adverse events, clinical laboratory values, and assessments for impulsive-compulsive disorders and sleepiness.

Original Source(s)

Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial

  • by Rajesh Pahwa, Elena Moro, Alberto J. Espay, Andrew Evans, Marie Saint-Hilaire, Diego Torres-Russotto, Raymond Sanchez, Matthew Leoni, Sridhar Duvvuri, Cari Combs, Ih Chang, Stacey Tringali, Joey Boiser, Cindy Zadikoff, Angelo Antonini

  • May 1, 2026

Related Content

Editorial: AI-powered advances in diagnosis and management of movement disorders

Exposure to Air Pollutants and Lewy Body and Parkinson Disease–Related Dementias

Intermittent Theta-Burst Stimulation for Depressive Symptoms in Parkinson Disease: A Randomized Clinical Trial